Approved indications
Recarbrio is FDA-approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), and for complicated urinary tract infections (cUTI, including pyelonephritis) and complicated intra-abdominal infections (cIAI) caused by susceptible Gram-negative bacteria in adults and pediatric patients weighing at least 2 kg, with use in cUTI and cIAI reserved for situations where there are limited or no alternative treatment options.

Off-label uses
Clinicians may use Recarbrio off-label as salvage therapy for other severe multidrug-resistant Gram-negative infections (such as bloodstream infections or complicated pneumonia outside the labeled settings) due to carbapenem-resistant Enterobacterales or Pseudomonas, but evidence comes mainly from small clinical studies and case series rather than large randomized trials.

Efficacy expectations
Fever and other infection symptoms often begin to improve within 2–3 days, though full treatment typically lasts 4–14 days depending on the site and severity of infection; clinical cure rates in trials were comparable to or better than standard comparator regimens, and the addition of relebactam extends activity against some carbapenem-resistant organisms compared with imipenem alone or older carbapenems.

Typical dosing and administration
Recarbrio is given only by intravenous infusion in a hospital, clinic, or occasionally by a supervised home-infusion service.

• Adults with normal kidney function: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) infused over 30 minutes every 6 hours.
• Pediatric patients weighing at least 2 kg: 37.5 mg/kg (imipenem 15 mg/kg, cilastatin 15 mg/kg, relebactam 7.5 mg/kg) every 6–8 hours, usually infused over 60 minutes when body weight is under 30 kg, with 1.25 g every 6 hours used for those weighing 30 kg or more.
• Typical treatment duration is 4–14 days, guided by the type and severity of infection and the patient’s clinical response.

Special dosing instructions
Doses must be reduced in adults and larger children with decreased kidney function, and the drug is not recommended for patients with very severe renal impairment (or very low estimated glomerular filtration rate) unless they are receiving hemodialysis, in which case individualized dosing is usually scheduled after dialysis sessions.

Missed doses and overdose
Because Recarbrio is administered by healthcare professionals on a fixed schedule, missed or delayed doses are typically given as soon as feasible without doubling the next dose, and suspected overdose is managed in a medical setting with supportive care and, when appropriate, hemodialysis to help remove the drug.

Common side effects
Most people tolerate Recarbrio well; common effects (often in roughly 5–10% of patients) include diarrhea, nausea or vomiting, headache, fever, increases in liver enzymes on blood tests, high blood pressure, anemia, low blood sodium or potassium, and pain, redness, or swelling where the IV is placed, usually starting during the course and generally mild to moderate in severity.

Serious or rare adverse effects
Serious reactions that need immediate medical attention can include severe allergic reactions (such as rash, hives, trouble breathing, or swelling of the face or throat), seizures or confusion (especially in people with brain disease or kidney problems), severe or persistent diarrhea that may signal Clostridioides difficile infection, kidney problems (such as decreased urine output or swelling), blood disorders (unusual bruising, bleeding, or paleness), or severe skin reactions.

Warnings and precautions
Recarbrio must not be used in anyone with a history of severe hypersensitivity to imipenem, other carbapenems, or serious reactions to other beta-lactam antibiotics (such as penicillins or cephalosporins); dose adjustment and close monitoring are needed in kidney impairment, caution is advised in patients with a history of seizures or other central nervous system disease, and those with significant liver disease may require additional monitoring of liver tests.

Use in pregnancy, breastfeeding, and special populations
Data in pregnancy and breastfeeding are limited, so Recarbrio is generally reserved for situations where the benefits of treating a serious infection clearly outweigh potential risks; it is approved for adults and pediatric patients from term birth weighing at least 2 kg, is not recommended below that threshold or in certain children with severe renal impairment, and older adults may be more susceptible to adverse effects if kidney function is reduced.

Overall safety profile and reporting
The safety profile of Recarbrio is broadly similar to that of other carbapenem antibiotics, without major new safety signals from the relebactam component, though seizure risk remains a recognized class effect in susceptible patients; side effects can be reported to regulators such as the U.S. FDA through the MedWatch program (online or by calling 1-800-FDA-1088) for ongoing safety monitoring.

Drug and other interactions
Important interactions include carbapenem-related lowering of blood levels of valproic acid/valproate, which can lead to loss of seizure control and is generally avoided; a potentially higher risk of seizures when combined with other medicines that lower the seizure threshold (such as some antidepressants, antipsychotics, or high-dose bupropion), particularly in patients with kidney impairment; and an increased chance of kidney-related side effects when used with other nephrotoxic drugs like aminoglycosides or high-dose diuretics, while clinically relevant interactions with food are not expected because the drug is given intravenously and alcohol has no direct interaction but may worsen overall illness or interact with other concurrent medicines.

Conditions requiring extra caution
Use Recarbrio with special care in people with a history of severe beta-lactam allergy, seizure disorders or other central nervous system disease, kidney impairment, significant liver disease, or in very young infants below the recommended age and weight limits, and ensure that dosing has been appropriately adjusted for renal function.

Monitoring
During therapy, clinicians typically monitor kidney function, liver enzymes, and blood counts, and watch for clinical signs of allergy, seizures, or antibiotic-associated diarrhea; specific drug level monitoring is not usually required for Recarbrio itself, but extra laboratory tests may be needed when it is used alongside interacting medicines such as valproate or in critically ill patients.

Q: What infections is Recarbrio used to treat?
A: It is used for serious hospital-acquired and ventilator-associated pneumonia, complicated urinary tract infections (including kidney infections), and complicated intra-abdominal infections caused by certain Gram-negative bacteria.

Q: How quickly will I start to feel better on Recarbrio?
A: Many people begin to notice improvement, such as lower fever and less breathing or abdominal discomfort, within 2–3 days, but the full course is usually continued for 4–14 days to completely treat the infection.

Q: What are the most common side effects of Recarbrio?
A: The most common problems are diarrhea, nausea or vomiting, headache, changes in liver blood tests, fever, and pain or irritation where the IV is placed.

Q: Can Recarbrio be used if I have kidney problems?
A: Recarbrio can be used in many patients with kidney impairment, but the dose must be adjusted and very severe kidney failure without dialysis is usually a reason to avoid it, so kidney function is checked before and during treatment.

Q: Is Recarbrio safe during pregnancy or breastfeeding?
A: Human data are limited, so Recarbrio is generally reserved in pregnancy or breastfeeding for situations where the expected benefits of treating a serious infection clearly outweigh potential risks, and the decision is made on a case-by-case basis.

Storage
Recarbrio vials and premixed bags are usually stored and prepared by healthcare professionals; if you are given doses at home, keep them exactly as instructed by your pharmacy (typically at room temperature or in the refrigerator), protect from extreme heat or freezing, and keep all supplies out of the reach of children and pets.

Disposal
Do not reuse leftover solution, needles, or tubing; any unused or expired medicine and used infusion materials should be returned to your clinic or pharmacy or disposed of in sharps or biohazard containers according to local instructions, not in household trash or sinks.